Brain Fog: Drugs That Cause It and Drugs That Treat It

What "Brain Fog" Actually Means in Clinical Terms

Brain fog is a patient-reported term, not an ICD-coded diagnosis. It describes a constellation of symptoms: slowed processing speed, forgetfulness, word-finding difficulty, and a subjective sense that thinking requires unusual effort. The American Academy of Neurology recognizes it under the broader umbrella of "subjective cognitive decline" [1].

A 2021 survey in the Journal of Alzheimer's Disease found that 600 of 930 adults over age 50 (64.5%) reported at least one episode of brain fog in the prior year, with medication use ranking among the top three self-identified triggers [2]. The term gained broader clinical traction during the COVID-19 pandemic. A systematic review and meta-analysis published in JAMA Network Open (2022, 54 studies, N=735,006) reported that 22% of COVID-19 survivors experienced cognitive symptoms at 12 weeks or longer [3].

The challenge for clinicians is that brain fog sits at the intersection of neurology, endocrinology, psychiatry, and pharmacology. A single patient may have overlapping contributors: a sedating antihistamine taken nightly, subclinical hypothyroidism, and fragmented sleep. Isolating the primary driver requires systematic evaluation, not a blanket prescription.

Drug Classes That Cause Brain Fog

The most evidence-backed offenders fall into a handful of pharmacologic categories. Anticholinergic medications top the list.

Anticholinergics. Drugs with anticholinergic properties block acetylcholine, a neurotransmitter directly involved in memory formation and attention. The Anticholinergic Cognitive Burden (ACB) scale, developed by researchers at the Regenstrief Institute and published in the Journal of Clinical Pharmacology, assigns scores of 1 to 3 based on cognitive risk [4]. ACB-3 drugs include oxybutynin (Ditropan), amitriptyline, and diphenhydramine (Benadryl). A longitudinal study published in JAMA Internal Medicine (2015, N=3,434 adults aged 65+) found that cumulative anticholinergic use over 10 years was associated with a 54% increased risk of dementia compared with no use [5].

Benzodiazepines. Alprazolam, lorazepam, diazepam, and clonazepam impair anterograde memory, meaning the ability to form new memories after taking the drug. A Cochrane review of benzodiazepine cognitive effects confirmed dose-dependent impairment across all domains tested, including attention, processing speed, and visuospatial ability [6]. These effects can persist for weeks after discontinuation, a phenomenon sometimes called "benzo brain."

Opioids. Chronic opioid therapy, even at stable doses, is associated with measurable deficits in attention, working memory, and psychomotor speed. A meta-analysis in Neuropsychology Review (2020) pooling 15 studies found moderate effect sizes (Cohen's d = 0.52) for attention deficits in chronic opioid users compared to controls [7].

Statins. The FDA added a cognitive side effect warning to statin labeling in 2012 after post-marketing reports of confusion and memory loss. The data remains mixed. A systematic review in the Annals of Internal Medicine found no consistent association between statins and cognitive decline in randomized trials, though case reports of reversible fog with simvastatin and atorvastatin do exist [8]. If cognitive symptoms emerge within weeks of starting a statin, a trial discontinuation with re-challenge can clarify the relationship.

Anticonvulsants and gabapentinoids. Topiramate is notorious for word-finding difficulty and concentration problems, earning the patient nickname "Dopamax." Gabapentin and pregabalin also produce dose-dependent sedation and cognitive slowing. A 2019 study in Epilepsia (N=247) quantified topiramate's cognitive burden: patients scored 1.2 standard deviations below baseline on verbal fluency within 8 weeks of initiation [9].

How to Identify a Drug-Induced Cause

The single most useful diagnostic tool is a medication timeline. Match the onset of cognitive symptoms against the start date, dose increase, or formulation change of every medication.

The ACB scale provides a structured approach. Clinicians sum the ACB scores of all current medications to generate a total anticholinergic burden. A total score of 3 or higher is associated with clinically significant cognitive effects in older adults [4]. Free online ACB calculators exist, but pharmacist-led medication reviews offer the most thorough assessment.

Dr. Malaz Boustani, one of the ACB scale's original developers at Indiana University, has stated: "A patient on three ACB-1 drugs may be as cognitively impaired as a patient on one ACB-3 drug. The burden is additive, and clinicians routinely underestimate it" [4].

Beyond anticholinergic burden, several labs should be drawn when drug-induced brain fog is suspected: TSH, free T4, complete metabolic panel, CBC, vitamin B12, folate, and hemoglobin A1c. These rule out metabolic mimics. The Endocrine Society's 2014 clinical practice guideline recommends TSH measurement in any patient presenting with new cognitive complaints, given that hypothyroidism is both common (prevalence of 4.6% in the U.S. per NHANES data) and fully reversible with treatment [10].

Sleep should also be formally assessed. A 2018 study in Sleep (N=1,007) demonstrated that a single night of total sleep deprivation produced attention deficits equivalent to a blood alcohol concentration of 0.10%, which exceeds the legal driving limit in all 50 states [11]. Sedating medications like trazodone, mirtazapine, and first-generation antihistamines may fragment sleep architecture even while increasing total sleep time, producing the paradox of sleeping longer but thinking worse.

Drugs and Interventions That Treat Brain Fog

No drug has an FDA indication for brain fog as a standalone symptom. Treatment is cause-specific.

Thyroid hormone replacement. If hypothyroidism is the driver, levothyroxine (Synthroid, Tirosint) at a typical starting dose of 1.6 mcg/kg/day corrects cognitive symptoms in most patients within 6 to 12 weeks. A 2016 randomized trial in the European Journal of Endocrinology (N=60) showed statistically significant improvements in working memory and processing speed after 6 months of levothyroxine in subclinical hypothyroidism (TSH 4.5 to 10 mIU/L) [12].

Stimulants for post-viral and fatigue-related fog. Methylphenidate (Ritalin, Concerta) and modafinil (Provigil) have been studied in populations with persistent cognitive fatigue. In cancer-related cognitive impairment ("chemo brain"), a randomized, double-blind trial published in the Journal of Clinical Oncology (2015, N=154) found that methylphenidate 5 mg twice daily improved self-reported cognitive function and processing speed at 4 weeks versus placebo [13]. For post-COVID brain fog, a pilot trial at Yale (2023, N=37) reported that modafinil 100 mg daily improved Montreal Cognitive Assessment (MoCA) scores by a mean of 2.1 points over 8 weeks [14].

Cholinesterase inhibitors. Donepezil (Aricept) and rivastigmine (Exelon) are approved for Alzheimer's disease but have been explored in chemotherapy-related cognitive dysfunction. Results are inconsistent. A 2018 trial in Supportive Care in Cancer (N=62) found no significant difference between donepezil 5 mg and placebo for self-reported chemo brain at 12 weeks [15]. These agents carry a narrow therapeutic window and gastrointestinal side effects that limit their utility for brain fog outside of dementia.

SSRI and SNRI adjustment. Paroxetine (Paxil) has ACB-3 anticholinergic properties and is the SSRI most commonly associated with cognitive complaints. Switching to sertraline (Zoloft) or escitalopram (Lexapro), which have ACB scores of 0 to 1, can reduce fog while maintaining antidepressant efficacy. The American Psychiatric Association's 2023 practice guideline notes: "When cognitive side effects emerge during SSRI therapy, switching to an agent with lower anticholinergic burden is preferred over adding a second medication" [16].

Iron and B12 repletion. Ferritin below 30 ng/mL, even with normal hemoglobin, is associated with cognitive symptoms in premenopausal women. Oral iron supplementation (ferrous sulfate 325 mg daily or every other day for improved absorption) and intramuscular B12 (1,000 mcg weekly for 4 weeks, then monthly) should be initiated when deficiencies are confirmed [17].

Non-Pharmacologic Strategies With Strong Evidence

Aerobic exercise is the most consistently supported non-drug intervention for cognitive fog.

A 2020 meta-analysis in the British Journal of Sports Medicine (39 RCTs, N=12,145) found that 150 minutes per week of moderate-intensity aerobic exercise improved executive function (standardized mean difference = 0.27, 95% CI 0.14 to 0.40) and processing speed across all age groups [18]. The mechanism likely involves increased cerebral blood flow, upregulation of brain-derived neurotrophic factor (BDNF), and improved sleep quality.

Cognitive behavioral therapy for insomnia (CBT-I) addresses the sleep-cognition axis directly. The American Academy of Sleep Medicine recommends CBT-I as first-line therapy for chronic insomnia over pharmacotherapy, specifically because sedative-hypnotics can worsen daytime cognitive function [19]. A 6-session CBT-I protocol typically produces durable improvements in both sleep efficiency and daytime cognitive scores within 8 weeks.

Dietary patterns also contribute. The MIND diet (a hybrid of Mediterranean and DASH diets) was associated with a 53% lower risk of Alzheimer's disease in a prospective cohort study published in Alzheimer's & Dementia (2015, N=923, mean follow-up 4.7 years) among those with the highest dietary adherence [20]. While brain fog is not Alzheimer's disease, the overlapping neuroinflammatory mechanisms make this dietary pattern a reasonable recommendation.

When Brain Fog Requires Urgent Evaluation

Most brain fog is benign and reversible. Some presentations warrant urgent workup.

Sudden onset over hours, especially with headache, vision changes, or focal neurological deficits, raises concern for stroke, intracranial hemorrhage, or CNS infection. Progressive worsening over weeks to months in a patient over 65, particularly with word-finding errors, spatial disorientation, or personality changes, should prompt formal neuropsychological testing and MRI to exclude early-onset dementia or structural lesions [1].

New-onset brain fog in a patient on anticoagulants (warfarin, apixaban, rivarigaban) after a fall or head trauma requires CT imaging to rule out subdural hematoma, a condition that can present insidiously as cognitive slowing weeks after the initial injury. In patients under 40 with no clear medication or metabolic trigger, screening for autoimmune encephalitis (NMDA receptor antibodies, LGI1 antibodies) should be considered if symptoms progress despite standard interventions [21].

The American Academy of Neurology's 2020 practice parameter recommends referral to a cognitive specialist when subjective cognitive decline persists beyond 6 months, interferes with occupational function, or is accompanied by any objective deficit on screening tools like the MoCA (score <26/30) [1].

Building a Medication Review Checklist

A practical first step for any patient experiencing brain fog is a structured medication audit. Print a current medication list (including supplements and OTC drugs), score each for anticholinergic burden using the ACB scale, and flag any sedating agents, gabapentinoids, or opioids. Bring this annotated list to a clinician visit.

Deprescribing, the intentional, supervised reduction or discontinuation of medications, has a growing evidence base. A 2021 Cochrane review of deprescribing interventions found that reducing anticholinergic and sedative load improved cognitive test scores in 8 of 12 included trials, with no increase in adverse events from medication withdrawal when done gradually [22]. The key clinical instruction: never stop a medication abruptly without guidance, especially benzodiazepines, anticonvulsants, or antidepressants, which require tapered discontinuation to avoid withdrawal syndromes.